Analyst picks & changes

By BC Staff | Oct 25, 1993 | 7:00 AM GMT

Gilead Sciences Inc.

(GILD)

Hambrecht & Quist analyst Timothy Wilson repeated a "buy" following presentation of "encouraging" data on GILD's

GS 504

antiviral compound at the

Read the full 274 word article

How to gain access

Continue reading with a
two-week free trial.